Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Endocrinology > Type II DM > Flashcards

Type II DM Flashcards

1
Q

Type II DM

-pathophysiology

A
  • body makes insulin but the tissues do not response well to it
  • insulin resistance: excess adipose tissue –> free fatty acids + adipokines = inflammation
  1. increase insulin production
  2. beta cell hyperplasia and hypertrophy
  3. normoglycemia
  4. beta cells secrete amylin
  5. amylin builds up
  6. hypoplasia and hypertrophy of beta cells
  7. insulin levels decrease
  8. hypergylcemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type II DM

  • symptoms (4)
  • complications (7)
A

-polyphagia, polyuria, polydipsia, glycosuria

  • hyaline atherosclerosis,
  • thickened b.m in capillaries = hypoxia
  • atherosclerosis
  • retinopathy
  • nephrotic syndrome
  • diabetic neuropathy - decreased sensation in toes and fingers
  • ulcers –> poor nerve supply + nerve damage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Diabetic ketoacidosis is less common in DM type I or II?

A

Type II DM because some insulin is still being produced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Main targets DM treatment (3)

A
  1. glycemic control - HbA1c
  2. cholesterol
  3. BP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Serum insulin and C-peptide levels in DM I and II

A

DM I –> lower levels

DM II –> high or normal levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cases when hypoglycemia can develop (2)

A
  1. if dose of insulin is too high
  2. if medications given directly stimulate insulin secretion without reacting with plasma glucose –> only medications like that: Sulphonylureas and Glinides
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Metformin

  • mode of action
  • can it be used together with insulin therapy?
  • clinical utility
  • contraindications
  • side effects
A
  • decrease hepatic glucose production and increase insulin-mediated peripheral glucose uptake
  • yes
  • first line - can be combined with any other medication
  • doest not cause hypoglycemia or weight gain

-contraindicated if eGFR <30 ml/min

  • diarrhea, abdominal discomfort
  • lactic acidosis - if prescribed improperly
  • vit B12 deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Metformin

-recommendations to decrease side effects (4)

A
  • start first dose in the evening before going to bed
  • start from the smallest dose –> if patient is tolerant –> increase dose
  • increase dose to maximum tolerated OR maximum therapeutic dose
  • titration period may take up to 1 month
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sulphonylureas

  • mode of action
  • clinical utility
  • contraindications
  • side effects (2)
A
  • increase endogenous insulin secretion by binding to pancreatic beta cells and triggering a cascade of intracellular events (does not react to plasma glucose levels)
  • can be combined with any other medication but risk of hypoglycemia will increase
  • if eGFR <30 ml/min
  • hypoglycemia and weight gain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Glinides

  • mode of action
  • difference when compared to Sulphonylureas
  • side effects (2)
A
  • increase insulin secretion by binding to pancreatic beta cells and triggering a cascade of intracellular events
  • stimulation of insulin secretion is more rapid and short lasting
  • hypoglycemia and weight gain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Alpha-glucosidase inhibitors

  • mode of action
  • side effects
A
  • inhibit enzymes that degrade oligosaccharides and disaccharides in the small intestine
  • flatulence and abdominal discomfort
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Thiazolidinedione

  • mode of action
  • clinical utility
  • side effects (3)
A
  • decrease insulin resistance by increasing the sensitivity of muscle and adipose cells to insulin and suppressing hepatic glucose production
  • does not cause hypoglycemia, maximal clinical effect is expected in a few weeks after starting
  • weight gain, edema, increased LDL
  • may exacerbate or precipitate CHF
  • increased risk of myocardial events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Thiazolidinedione

  • contraindications (2)
  • can it be used together with insulin?
A
  • patients with abnormal liver function
  • increased risk for bladder cancer

-no, it increases the risk of fluid retention specially in patients with heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

The incretin system

A
  • plays a key role in regulation of post-meal glucose
  • incretin effect –> increases beta cell response to oral glucose –> a greater insulin release than when the same amount of glucose is given IV
  • increase C-peptide levels after oral glucose load
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The incretin system

-Glucagon- like peptide (GLP-1) - function (7)

A
  • increases insulin secretion in a glucose dependent manner
  • enhances glucose-dependent insulin secretion and decrease postprandial glucagon secretion
  • increase glucose uptake by peripheral tissue and decrease hepatic glucose production = decrease blood glucose in fasting and postprandial states
  • promotes satiety and reduces appetite
  • helps regulate gastric emptying
  • enhances B cell proliferation
  • secreted by intestinal L-cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

GLP-1 is mot responsive to…?

Actions are mediated via…?

A

-Lipids and amino acids

  • GLP-1R
  • receptors are expressed in beta cells
  • when activated –> activates cAMP and protein kinase A dependent and independent actions
17
Q

DPP-4 inhibitors

  • mode of action
  • clinical utility (3)
  • cannot be used in combination with…?
  • side effects (3)
A
  • prolong the effects of GLP-1 and GIP on alpha and beta cells leading to increased insulin secretion and decreased glucagon secretion
  • does not cause hypoglycemia, can be combined with any other medication, very good for elderly patients, dose should be reduced in renal insufficiency
  • GLP-1RA because they work on the same system (incretin system)
  • upper respiratory tract infection, nasopharyngitis and headache
18
Q

GLP-1RA

  • mode of action
  • clinical utility (4)
  • contraindication
  • side effects (4)
A
  • mimic the effects of endogenous GLP-1 by activating GLP-1 receptors throughout the body
  • they are synthetic incretins
  • increase insulin, decrease glucagon, slow gastric emptying
  • increase glucose uptake by peripheral tissue, decrease hepatic glucose production
  • low risk of hypoglycemia, weight reduction, reduction in postprandial glucose excursions ,injectable (requires training)
  • eGFR <15 ml/min
  • nausea, vomiting, diarrhea, risk of acute pancreatitis,
19
Q

The role of kidney in glucose handling (4)

A
  • kidney reabsorbs and recirculates glucose
  • 90% - reabsorbed in proximal tubule (S1 segment) - facilitate by SGLT2
  • 10% - reabsorbed in proximal tubule (S3 segment) - facilitate by SGLT1
  • minimal or no glucose excretion in urine
20
Q

The role of SGLT

  • SGLT1 (2)
  • SGLT2 (3)
A

SGLT1

  • main uptake mechanism for glucose and galactose in the intestine
  • high-affinity, low-capacity transporter

SGLT2

  • in the brush-border membrane of the proximal renal tubular cells in the S1 + S2 segment
  • responsible for around 90% of the total renal glucose re-absorption
  • low-affinity, high-capacity transporter
21
Q

SGLT2 inhibitors

  • mode of action
  • clinical utility (4)
  • contraindication
  • side effects (3)
A
  • reduce renal tubular glucose reabsorption = reduce blood glucose without stimulating insulin release
  • can be combined with any other medication, low risk of hypoglycemia, weight loss, BP reduction
  • eGFR <45 ml/min
  • genital and urinary tract infections
  • risk of normoglycemic ketoacidosis
  • volume depletion, hypovolemia and hypotension
22
Q

If a patient with type II DM is a high risk patient OR has established ASCVD, CKD or HF, consider add which drugs?

A
  • GLF-RA or SGLT2 inhibitors

- irrespectively of baseline or individualized HbA1c

23
Q

GLP-1 RA recommendations

A

For patients with type 2 diabetes and established:

  • atherosclerotic CV disease with prior MI,
  • ischemic stroke,
  • unstable angina with ECG changes
  • other MACE (major adverse cardiac events)

basically –> if Atherosclerotic cardiovascular disease (ASCVD) predominates

24
Q

SGLT-2 recommendations

A

For patients with type 2 diabetes:

  • with or without established atherosclerotic CVC but with HF,
  • with foot ulcers or at high risk for amputation,
  • to prevent the progression of CKd, HF, MACE and CV death

basically –> if heart failure (HF) or chronic kidney disease (CKD) predominates

25
Q

When to start insulin therapy in type II diabetes patients?

A

When combinations with oral medications become ineffective - when HbA1c levels >10%-12
Blood glucose levels are very high >16.7-19,9 mmol/l
OR
In urgent situations –> ex: pneumonia, MI, stroke, ketoacidosis
OR
If there is evidence of ongoing catabolism (weight loss)

26
Q

How to choose the HbA1c target?

A

If diabetes diagnosed for the first time, healthy patients –> less than 6.5%
Elderly patient with cardiovascular risk factors –> 7.0-7.5%

the closer we are to normal HbA1c as a healthy person, the higher the risk of hypoglycemia

27
Q

Diabetic nephropathy

A
  • reduction of GFR + protein in urine
  • necessary to analyze the albumin to creatinine ratio in urine

Normal GFR - 90 or higher
Kidney failure - less than 15
Normal albumin in urine - <30 mg/g
Severe high albumin in urine - >300 mg/g

28
Q

Hyperglycemic hyperosmolar state (HHS)

-pathophysiology

A

-extremely high blood sugar + high osmolarity (too much pee)

  1. increase glucose levels
  2. water leaves cells and enters blood vessels
  3. urination increases
  4. severe dehydration
29
Q

Hyperglycemic hyperosmolar state (HHS)

-diagnosis (4)

A
  • absence of ketones
  • plasma osmolarity >320
  • increase enzymes - albumin, amylase, creatinine kinase
  • plasma glucose >600 mg/dl
30
Q

Hyperglycemic hyperosmolar state (HHS)

-treatment

A
  • fluid replacement before insulin to avoid circulatory collapse
  • electrolyte hemostasis
  • treat underlying disease
  • airway management
31
Q

How to calculate plasma osmolarity?

A

2 Na + glucose + urea

normal - 285-295

32
Q

Which condition is more dangerous DKA or HHS?

A

HHS because patients are most of time unconscious and elderly people which usually have concomitant diseases.

33
Q

HHS most common cause of death

A

Brain edema

34
Q

Most effective GLP-1RA

A

Semaglutide

35
Q

How to choose HbA1c target?

A
  • diabetes diagnosed for the 1st time –> less than 6.5%
  • elderly patient + risk factors –> 7.0-7.5%
  • healthy patient –> less than 6.5%
  • short life expectancy –> above 7.0%

the closer we are to normal HbA1c as a healthy person –> the higher the risk of hypoglycemia

Endocrinology (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions